Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NewGenIvf Group Limited Class A Ordinary Shares (NIVF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: NIVF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -4.07% | Avg. Invested days 65 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.45M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.13 | 52 Weeks Range 0.26 - 45.40 | Updated Date 06/29/2025 |
52 Weeks Range 0.26 - 45.40 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -293.1 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -9.66% | Operating Margin (TTM) -85.51% |
Management Effectiveness
Return on Assets (TTM) -17.99% | Return on Equity (TTM) -53.76% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7113172 | Price to Sales(TTM) 0.82 |
Enterprise Value 7113172 | Price to Sales(TTM) 0.82 | ||
Enterprise Value to Revenue 1.31 | Enterprise Value to EBITDA 294.99 | Shares Outstanding 4304040 | Shares Floating 112699 |
Shares Outstanding 4304040 | Shares Floating 112699 | ||
Percent Insiders 2.24 | Percent Institutions 0.55 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
NewGenIvf Group Limited Class A Ordinary Shares
Company Overview
History and Background
NewGenIvf Group Limited, a fertility treatment provider based in Singapore, has expanded its operations regionally, focusing on Southeast Asia. The Class A Ordinary Shares represent ownership in the company. Founded with the aim of providing advanced fertility solutions, it has grown through acquisitions and organic expansion.
Core Business Areas
- In-Vitro Fertilization (IVF): Offers a comprehensive range of IVF services, from initial consultations to embryo transfer, utilizing advanced technologies and personalized treatment plans.
- Intracytoplasmic Sperm Injection (ICSI): Specializes in ICSI, a procedure used to assist fertilization by directly injecting a single sperm into an egg.
- Fertility Screening and Diagnostics: Provides diagnostic services to assess fertility potential, including sperm analysis, ovarian reserve testing, and genetic screening.
- Other Assisted Reproductive Technologies (ART): Offers a variety of other ART services, such as egg freezing, sperm freezing, and preimplantation genetic testing (PGT).
Leadership and Structure
Details about NewGenIvf's specific leadership and organizational structure are not available in public SEC filings at the time of this knowledge cut-off. Further research on the company's website and official documentation would be necessary to fill this gap.
Top Products and Market Share
Key Offerings
- IVF Treatment Cycles: IVF treatment cycles are a core revenue generator, encompassing consultations, monitoring, egg retrieval, fertilization, and embryo transfer. The market share data is not readily available publicly but can be indirectly estimated by looking at total revenue. The competitors for this product are other IVF clinics and hospitals offering fertility treatments.
- Fertility Screening and Diagnostics: This includes a range of tests to assess fertility potential in both men and women. The market share for NewGenIvf's fertility screening services is also not publicly available, but they are likely competitive in Singapore and other SEA markets where they operate. The competitors in this category include diagnostic labs and other fertility centers.
Market Dynamics
Industry Overview
The fertility services industry is growing globally, driven by factors such as delayed childbearing, increasing infertility rates, and advancements in assisted reproductive technologies. The market is competitive, with numerous clinics and hospitals offering similar services.
Positioning
NewGenIvf positions itself as a provider of advanced and personalized fertility solutions, focusing on quality and patient care. They aim to attract patients seeking comprehensive and effective fertility treatments.
Total Addressable Market (TAM)
The global IVF market is estimated to reach billions of dollars, with significant growth potential in emerging markets. NewGenIvf is positioned to capture a portion of this market through its regional focus and service offerings.
Upturn SWOT Analysis
Strengths
- Regional Presence in Southeast Asia
- Comprehensive Range of Fertility Services
- Experienced Medical Professionals
- Utilization of Advanced Technologies
Weaknesses
- Relatively Small Market Capitalization
- Limited Brand Recognition Compared to Larger Players
- Dependence on Regulatory Environment
- Information on specific financials are still needed to complete the picture on the company's financial performance
Opportunities
- Expansion into New Geographic Markets
- Increasing Demand for Fertility Treatments
- Strategic Partnerships with Hospitals and Clinics
- Development of New Fertility Technologies
Threats
- Competition from Larger Fertility Clinics
- Changes in Government Regulations
- Economic Downturn Affecting Patient Spending
- Ethical Concerns Regarding ART
Competitors and Market Share
Key Competitors
- TSRI
- FGEN
Competitive Landscape
NewGenIvf faces competition from larger and more established fertility clinics and hospitals. Its advantages may include its regional focus, personalized service, and use of advanced technologies. Its disadvantages might stem from its smaller size and brand recognition.
Growth Trajectory and Initiatives
Historical Growth: Details on historical growth data for NewGenIvf is still pending, in order to show the trends.
Future Projections: Future projections on NewGenIvf is still pending. Analyst consensus, where available, would also be important to show.
Recent Initiatives: Details regarding NewGenIvf is still pending and needs to be provided to show the recent strategic initiative and progress.
Summary
NewGenIvf Group Limited is a fertility treatment provider with a focus on Southeast Asia, offering a comprehensive range of ART services. The company's strengths include its regional presence and experienced medical professionals, but it faces challenges related to its small market cap and intense competition. Opportunities exist for expansion and partnerships, while threats include regulatory changes and economic downturns. More financial data is needed for in-depth performance review.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings
- Company website
- Industry reports
Disclaimers:
The information provided is based on publicly available data and may not be comprehensive. This analysis is for informational purposes only and does not constitute investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NewGenIvf Group Limited Class A Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2024-04-03 | Co-Founder, Chairman & CEO Mr. Wing Fung Siu | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 76 | Website https://newgenivf.com |
Full time employees 76 | Website https://newgenivf.com | ||
NewGenIvf Group Limited, an investment holding company, provides an assisted reproductive service that helps couples and individuals for fertility treatments in Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The company's fertility treatment solutions include in vitro fertilization (IVF), ICSI, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screening, hysteroscopy, sperm analysis, sorting, washing, and freezing, and egg freezing. It also provides IVF treatment; surrogacy and ancillary caring services, including regular body check, as well as vitamins, supplements, and medicines to surrogate mothers; and value-added services comprising nutrition guidance, psychological counselling, acupuncture, and translation interpreters to supplement the IVF treatment. The company offers its services through its clinics. NewGenIvf Group Limited was founded in 2010 and is based in Bangkok, Thailand.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.